Patents by Inventor Jennifer Covello

Jennifer Covello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230137548
    Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.
    Type: Application
    Filed: July 11, 2022
    Publication date: May 4, 2023
    Applicant: CITY OF HOPE
    Inventors: Alexandra Jacqueline ANNALA, Karen ABOODY, Jennifer COVELLO, Rachael MOONEY
  • Patent number: 11413315
    Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: August 16, 2022
    Assignee: CITY OF HOPE
    Inventors: Alexandra Jaqueline Annala, Karen Aboody, Jennifer Covello, Rachael Mooney
  • Publication number: 20210052660
    Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and a replication-competent oncolytic virus such as conditionally replication-competent chimeric orthopoxvirus (CF33). The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.
    Type: Application
    Filed: April 30, 2019
    Publication date: February 25, 2021
    Inventors: Alexandra J. ANNALA, Karen S. ABOODY, Yuman FONG, Nanhai G. CHEN, Mohamed HAMMAD, Rachael MOONEY, Jennifer COVELLO
  • Publication number: 20200038453
    Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.
    Type: Application
    Filed: April 29, 2019
    Publication date: February 6, 2020
    Inventors: Alexander J. Annala, Karen Aboody, Jennifer Covello, Rachael Mooney